1-2 of 2
Heather Schneider, BSN, RN
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents

Guillermo Montalban Bravo, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Zeev E. Estrov, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Kelly S. Chien, MD, Graciela M. Nogueras González, MPH, Xiao Qin Dong, Stefan Faderl, MD, Heather Schneider, BSN, RN, Rosmy B. John, MSN, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–3.
https://doi.org/10.1182/blood-2020-139942
Published: 2020
Journal Articles

Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy

Yasmin Abaza, MD, Elias J. Jabbour, MD, Srdan Verstovsek, MD PhD, Zeev Estrov, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Naval Daver, MD, Courtney D DiNardo, MD, Carlos E. Bueso-Ramos, MD PhD, Juliana E. Hidalgo, MD, Heather Schneider, BSN, RN, Guillermo Montalban Bravo, MD, Ana Alfonso, MD, Yue Wei, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2016) 128 (22): 4318.
https://doi.org/10.1182/blood.V128.22.4318.4318
Published: 2016